insights_auto
Why is EII up 2,01%?
Dive Deeperchevron_right
EII:FRA
Eisai Co Ltd
28,97 €
arrow_upward
+2,01%(+0,57) 1D
13-ноя., 08:06:11 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EII...
Open
28,97 €
High
28,97 €
Low
28,97 €
Mkt. cap
1,51 трлн
Avg. vol.
239,00
Volume
0,00
52-wk high
31,02 €
52-wk low
19,70 €
No. of employees
11 миң
Open
28,97 €
High
28,97 €
Low
28,97 €
Mkt. cap
1,51 трлн
Avg. vol.
239,00
Volume
0,00
52-wk high
31,02 €
52-wk low
19,70 €
No. of employees
11 миң
News stories
From web sources and news partners
Yahoo Finance
·
10 саат мурун
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
Seeking Alpha
·
10 саат мурун
Eisai Co., Ltd. 2027 Q2 - Results - Earnings Call Presentation (OTCMKTS:ESAIY) 2026-11-12
finance.biggo.com
·
1 күн мурун
[Eisai FY2026 Q2 Earnings Call] Eisai Posts 20.4% Rise in Interim Operating Profit to ¥41.4 Billion - Subcutaneous Leqembi Winning Patients at 4x the Pace of IV; Full-Year ¥70 Billion Target "Aiming for Upside"
Investing.com
·
3 күн мурун
Eisai Q2 FY2026 slides: 3L products drive 17.5% revenue growth
Profile
Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices. Wikipedia
About Eisai Co Ltd
CEOHaruo Naito | Haruo Naito
Employees10,5 миң
Founded1941-ж., 6-дек.
HeadquartersBunkyo City, Tokyo, Япония
SectorHealth Care
IndustryPharmaceutical industry
Websiteeisai.co.jp